NCT04418661 - Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions

Metastatic Neoplasm

Interventions

DRUG

Vociprotafib

Pharmaceutical form: Varies Route of administration: Varies

DRUG

Pembrolizumab

Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion

DRUG

Adagrasib

Pharmaceutical form:Sterile Tablet Route of administration: Oral

Trial Locations (20)

100

Investigational Site Number : 1580001, Taipei

704

Investigational Site Number : 1580002, Tainan City

1019

Investigational Site Number : 0320001, Buenos Aires

1093

Investigational Site Number : 0320004, Buenos Aires

1125

Investigational Site Number : 0320002, Buenos Aires

2000

Investigational Site Number : 0320003, Rosario

2031

Investigational Site Number : 0360002, Sydney

3084

Investigational Site Number : 0360003, Melbourne

4102

Investigational Site Number : 0360001, Woolloongabba

13496

Investigational Site Number : 4100002, Seongnam-si

28040

Investigational Site Number : 7240001, Madrid

28050

Investigational Site Number : 7240002, Madrid

28644

Investigational Site Number : 4100003, Cheongju-si

46010

Investigational Site Number : 7240003, Valencia

77030

The University of Texas MD Anderson Cancer Center- Site Number : 8400001, Houston

92868

University of California Irvine Medical Center- Site Number : 8400002, Orange

2520598

Investigational Site Number : 1520003, Viña del Mar

4780000

Investigational Site Number : 1520002, Temuco

8420383

Investigational Site Number : 1520001, Santiago

03722

Investigational Site Number : 4100001, Seoul